Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Iomx Therapeutics AG is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, reflecting a singular focus for the company's active patent prosecution. The data shows that the portfolio is contained within 1 distinct art unit, which provides a stable and unified regulatory framework for their work.
The busiest examiner, BAEK, BONG-SOOK, is tasked with the 1 busiest examiner pending action currently on file. Because there is only 1 distinct examiner involved, the company's immediate patent goals are subject to the specific review of this one individual. This concentration allows the practitioner to develop a deep understanding of the examiner's requirements without the distraction of multiple pending cases.
The presence of 1 pending office action in the Biotechnology & Pharmaceuticals field suggests a focused level of active engagement with the USPTO. Since the portfolio only interacts with 1 distinct art unit, the legal strategy can remain highly specialized. Practitioners can focus their efforts on the 1 pending office action, ensuring that the arguments presented to BAEK, BONG-SOOK are consistent with the specific standards of that single art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17282508 | DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF | BAEK, BONG-SOOK | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17282508 | DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF | BAEK, BONG-SOOK | 7d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17282508 | DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF | BAEK, BONG-SOOK | 1611 | §102§103§112 | Final Rejection | 7d | Pending | Apr 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial